Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.1 An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients.

During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

Upon completion of this activity, participants will be better able to do the following:

• Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
• Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
• Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
• Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

There is no registration fee to complete this activity. 

Click here to register for this activity.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.